We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Blood Test Helps Detect Brain Injury in Minutes

By LabMedica International staff writers
Posted on 11 Sep 2019
After traumatic brain injury (TBI), plasma concentration of glial fibrillary acidic protein (GFAP) correlates with intracranial injury visible on computerized axial tomography (CT) scan. More...
Some patients with suspected TBI with normal CT findings show pathology on magnetic resonance imaging (MRI).

Recently scientists have found that a handheld blood analyzer could help detect brain injury within 15 minutes using a commercial system that measures GFAP and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) proteins from the brain that are released into the blood after a brain injury, They assessed the discriminative ability of GFAP to identify MRI abnormalities in patients with normal CT findings.

Neurologists at the University of California at San Francisco (San Francisco, CA, USA) and their associates enrolled patients with TBI who had a clinically indicated head CT scan within 24 hours of injury at 18 level 1 trauma centers in the USA. For this analysis, they included patients with normal CT findings (Glasgow Coma Scale score 13–15) who consented to venipuncture within 24 hours post injury and who had a MRI scan 7–18 days post injury. They compared MRI findings in these patients with those of orthopedic trauma controls and healthy controls recruited from the study sites.

Plasma GFAP concentrations (pg/mL) were measured using a prototype assay on a point-of-care platform, the hand-held blood analyzer, the i-STAT Alinity system. The scientists used receiver operating characteristic (ROC) analysis to evaluate the discriminative ability of GFAP for positive MRI scans in patients with negative CT scans over 24 hours (time between injury and venipuncture). The primary outcome was the area under the ROC curve (AUC) for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings within 24 hours of injury.

The team recruited between February 26, 2014, and June 15, 2018, 450 patients with normal head CT scans (of whom 330 had negative MRI scans and 120 had positive MRI scans), 122 orthopedic trauma controls, and 209 healthy controls. AUC for GFAP in patients with CT-negative and MRI-positive findings versus patients with CT-negative and MRI-negative findings was 0·777 over 24 hours. Median plasma GFAP concentration was highest in patients with CT-negative and MRI-positive findings (414.4 pg/mL), followed by patients with CT-negative and MRI-negative findings (74.0 pg/mL), orthopedic trauma controls (13.1 pg/mL), and healthy controls (8.0 pg/mL, all comparisons between patients with CT-negative MRI-positive findings and other groups.

The authors concluded that analysis of blood GFAP concentrations using prototype assays on a point-of-care platform within 24 hours of injury might improve detection of TBI and identify patients who might need subsequent MRI and follow-up. The study was published on August 23, 2019, in the journal The Lancet Neurology.

Related Links:
University of California at San Francisco


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.